Floatz logo

Enalapril Maleate

Essential Hypertension

Shenzhen Ausa Pharmed Co.,LtdUNKNOWNPhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Essential Hypertension cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
Yuhan Corporation
Phase 4BBB
AMLODIPINE
Yuhan Corporation
Phase 4BBB
Glibenclamide
University of Campinas, Brazil
Phase 4BB
Valsartan
ARKAY Therapeutics
Phase 4BB
Dapagliflozin
University of Campinas, Brazil
Phase 4BB

View all 43 →

Same molecule, other indications

Enalapril Maleate is also rated in:

hyperhomocysteinemiaDormant
BB
Indicative · Phase 4
69 / 100
View asset →
hypertensive disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →
childhood neoplasmDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →